标题
The role and therapeutic targeting of IL-6 in rheumatoid arthritis
作者
关键词
-
出版物
Expert Review of Clinical Immunology
Volume 13, Issue 6, Pages 535-551
出版商
Informa UK Limited
发表日期
2017-05-12
DOI
10.1080/1744666x.2017.1295850
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
- (2016) A Strangfeld et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
- (2016) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib for the treatment of rheumatoid arthritis
- (2016) Satoshi Kubo et al. Expert Review of Clinical Immunology
- Immunotherapeutic implications of IL-6 blockade for cytokine storm
- (2016) Toshio Tanaka et al. Immunotherapy
- Arid5a regulates naive CD4+T cell fate through selective stabilization of Stat3 mRNA
- (2016) Kazuya Masuda et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial
- (2016) Johannes W J Bijlsma et al. LANCET
- Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
- (2016) Peter M Villiger et al. LANCET
- Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
- (2016) Dinesh Khanna et al. LANCET
- Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group
- (2016) Yasuhiko Hirabayashi et al. Modern Rheumatology
- Rheumatoid arthritis: current and future trends
- (2016) Kritika Chaudhari et al. NATURE REVIEWS DRUG DISCOVERY
- Family history of rheumatoid arthritis: an old concept with new developments
- (2016) Thomas Frisell et al. Nature Reviews Rheumatology
- Arid5a exacerbates IFN-γ–mediated septic shock by stabilizing T-bet mRNA
- (2016) Mohammad Mahabub-Uz Zaman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling
- (2016) Lomeli R. Carpio et al. Science Signaling
- Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)
- (2016) T Takeuchi et al. VALUE IN HEALTH
- Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling
- (2016) Lomeli R. Carpio et al. Science Signaling
- Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine
- (2016) Yuichi Maeda et al. Arthritis & Rheumatology
- Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica
- (2016) Lindsay Lally et al. Arthritis & Rheumatology
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
- (2015) Cem Gabay et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future
- (2015) Go Woon Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- Regnase-1 and Roquin Regulate a Common Element in Inflammatory mRNAs by Spatiotemporally Distinct Mechanisms
- (2015) Takashi Mino et al. CELL
- Interleukin-6: Biology, signaling and strategies of blockade
- (2015) Fred Schaper et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues
- (2015) Gareth W. Jones et al. IMMUNOLOGY
- Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis
- (2015) Haifeng Hou et al. INFLAMMATION RESEARCH
- A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130
- (2015) Soon-Sun Hong et al. JOURNAL OF IMMUNOLOGY
- Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
- (2015) K. Yamamoto et al. JOURNAL OF RHEUMATOLOGY
- Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial
- (2015) Tsutomu Takeuchi et al. Modern Rheumatology
- Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
- (2015) Qian Zhang et al. NATURE
- IL-6 as a keystone cytokine in health and disease
- (2015) Christopher A Hunter et al. NATURE IMMUNOLOGY
- Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response
- (2015) Jun Kikuchi et al. ARTHRITIS RESEARCH & THERAPY
- Brief Report: Leucine-Rich α2-Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti-Interleukin-6 Biologic Therapy in Rheumatoid Arthritis
- (2015) Minoru Fujimoto et al. Arthritis & Rheumatology
- The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, Dose-Ra
- (2015) Michael E. Weinblatt et al. Arthritis & Rheumatology
- Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
- (2015) Vijay U. Rao et al. Arthritis & Rheumatology
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- (2015) Jasvinder A. Singh et al. Arthritis & Rheumatology
- Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
- (2014) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
- (2014) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases
- (2014) Christoph Garbers et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- IL-6-Dependent Mucosal Protection Prevents Establishment of a Microbial Niche for Attaching/Effacing Lesion-Forming Enteric Bacterial Pathogens
- (2014) S. M. Dann et al. JOURNAL OF IMMUNOLOGY
- Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis
- (2014) M. A. Nowell et al. JOURNAL OF IMMUNOLOGY
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
- (2014) Norihiro Nishimoto et al. Modern Rheumatology
- Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study
- (2014) M. Araki et al. NEUROLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis
- (2014) C. I. Daien et al. RHEUMATOLOGY
- A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy
- (2014) Toshio Tanaka et al. SEMINARS IN IMMUNOLOGY
- IL-6 in Inflammation, Immunity, and Disease
- (2014) T. Tanaka et al. Cold Spring Harbor Perspectives in Biology
- Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis
- (2013) Priscilla F Kerkman et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
- (2013) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- (2013) D. T. Teachey et al. BLOOD
- Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan
- (2013) T. Koike et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo
- (2013) Kazuya Masuda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
- (2013) Atsushi Ogata et al. ARTHRITIS CARE & RESEARCH
- Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis
- (2013) Jose U Scher et al. eLife
- AT-Rich-Interactive Domain-Containing Protein 5A Functions as a Negative Regulator of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt-Induced Th17 Cell Differentiation
- (2013) Yukari Saito et al. Arthritis & Rheumatology
- Interleukin-6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis
- (2013) A. Thiolat et al. Arthritis & Rheumatology
- Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblasts
- (2012) Olga Sanchez-Pernaute et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
- (2012) Vivian P Bykerk et al. ANNALS OF THE RHEUMATIC DISEASES
- Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
- (2012) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- The origins, function, and regulation of T follicular helper cells
- (2012) Cindy S. Ma et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study
- (2012) Michael E. Weinblatt et al. ARTHRITIS CARE & RESEARCH
- Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells
- (2011) K. Muhammad et al. ANNALS OF THE RHEUMATIC DISEASES
- Therapeutic Targeting of the Interleukin-6 Receptor
- (2011) Toshio Tanaka et al. Annual Review of Pharmacology and Toxicology
- In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment
- (2011) Petra Roll et al. ARTHRITIS AND RHEUMATISM
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model*
- (2011) Tanja Barkhausen et al. CRITICAL CARE MEDICINE
- IL-6 plays an essential role in neutrophilia under inflammation
- (2011) Misato Hashizume et al. CYTOKINE
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
- (2011) Simon A. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- The Pathogenesis of Rheumatoid Arthritis
- (2011) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
- (2011) Norio Chihara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab
- (2010) A. Ogata et al. ANNALS OF THE RHEUMATIC DISEASES
- Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: Implications for autoimmunity in rheumatoid arthritis
- (2010) Natalia Wegner et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
- (2010) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease
- (2010) S.-N. J. Song et al. BLOOD
- IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer
- (2010) Chi-Wen Lo et al. CANCER RESEARCH
- IL-6: Regulator of Treg/Th17 balance
- (2010) Akihiro Kimura et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Involvement of Autoimmunity in the Pathogenesis of Aggressive Periodontitis
- (2010) A. Hendler et al. JOURNAL OF DENTAL RESEARCH
- Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
- (2010) Tomoyuki Igawa et al. NATURE BIOTECHNOLOGY
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment
- (2009) S Nishida et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
- (2009) Sergei Grivennikov et al. CANCER CELL
- Heat Shock Protein 96 Is Elevated in Rheumatoid Arthritis and Activates Macrophages Primarily via TLR2 Signaling
- (2009) Q.-Q. Huang et al. JOURNAL OF IMMUNOLOGY
- Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay
- (2009) Kazufumi Matsushita et al. NATURE
- IL-6/sIL-6R trans-signalling, but not TNF-α induced angiogenesis in a HUVEC and synovial cell co-culture system
- (2009) Misato Hashizume et al. RHEUMATOLOGY INTERNATIONAL
- Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid Synovium
- (2009) Frances Humby et al. PLOS MEDICINE
- The role of Toll-like receptors in rheumatoid arthritis
- (2009) Qi-Quan Huang et al. Current Rheumatology Reports
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis
- (2008) Caroline Ospelt et al. ARTHRITIS AND RHEUMATISM
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
- (2008) N. Nishimoto et al. BLOOD
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
- (2008) Josef S Smolen et al. LANCET
- Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells
- (2008) A. Kimura et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- and IL-17
- (2008) M. Hashizume et al. RHEUMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started